Advanced search
Publication Cover
Postgraduate Medicine Volume 133, 2021 - Issue 3
Submit an article Journal homepage
4,554
Views
8
CrossRef citations to date
0
Altmetric
CLINICAL FEATUREREVIEW

Patient initiation and maintenance of GLP-1 RAs for treatment of obesity: a narrative review and practical considerations for primary care providers

Angela Fitcha Endocrine Unit, Division of Endocrinology, Department of Medicine and MGH Weight Center, Massachusetts General Hospital, Boston, MA, USA;b Harvard Medical School, Boston, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9912-5994
ORCID Icon &
Amy Beth Ingersollc Arizona Obesity Organization, Phoenix, AZ, USA
Pages 310-319 | Received 05 Aug 2020, Accepted 30 Oct 2020, Published online: 03 Dec 2020

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Janine V. Kyrillos, Neil S. Skolnik, Bhasha Mukhopadhyay & Nicholas Pennings. (2022) Integrating semaglutide into obesity management – a primary care perspective. Postgraduate Medicine 134:sup1, pages 37-49.
Read now

Articles from other publishers (7)

Konstantinos Arvanitakis, Theocharis Koufakis, Djordje Popovic, Giuseppe Maltese, Omar Mustafa, Michael Doumas, Olga Giouleme, Kalliopi Kotsa & Georgios Germanidis. (2023) GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations and Practical Recommendations for Safe and Effective Use. Current Obesity Reports 12:2, pages 61-74.
Crossref
Juan J. Gorgojo-Martínez, Pedro Mezquita-Raya, Juana Carretero-Gómez, Almudena Castro, Ana Cebrián-Cuenca, Alejandra de Torres-Sánchez, María Dolores García-de-Lucas, Julio Núñez, Juan Carlos Obaya, María José Soler, José Luis Górriz & Miguel Ángel Rubio-Herrera. (2022) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus. Journal of Clinical Medicine 12:1, pages 145.
Crossref
Andrew Grannell. (2022) Reframing the need for exercise therapy in the clinical management of people living with obesity. Clinical Obesity 12:6.
Crossref
Meng Yu, Zheng Yang, Chongxin Chen, Yuhuan Lv, Linyu Xiang, Subei Zhao & Rong Li. (2022) Association of the gallbladder or biliary diseases with dipeptidyl peptidase 4 inhibitors in patients with type 2 diabetes: a meta-analysis of randomized controlled trials. Diabetology & Metabolic Syndrome 14:1.
Crossref
Sean Wharton, Salvatore Calanna, Melanie Davies, Dror Dicker, Bryan Goldman, Ildiko Lingvay, Ofri Mosenzon, Domenica M. Rubino, Mette Thomsen, Thomas A. Wadden & Sue D. Pedersen. (2021) Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism 24:1, pages 94-105.
Crossref
Zhan Li, Sha Wang, Yiwei He, Qiong Li, Guoying Gao & Guoxiang Tong. (2021) Regulation of Apelin-13 on Bcl-2 and Caspase-3 and Its Effects on Adipocyte Apoptosis. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-8.
Crossref
Gautam Das. (2021) Liraglutide for overweight and obesity. Practical Diabetes 38:1, pages 7.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.